Get the Stockscreener App
23.46
1.76%
-0.42
Stoke Therapeutics Inc stock is traded at $23.46, with a volume of 1.03M.
It is down -1.76% in the last 24 hours and up +73.39% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$23.88
Open:
$24
24h Volume:
1.03M
Relative Volume:
1.32
Market Cap:
$1.29B
Revenue:
$199.89M
Net Income/Loss:
$52.48M
P/E Ratio:
27.60
EPS:
0.85
Net Cash Flow:
$61.15M
1W Performance:
+13.44%
1M Performance:
+73.39%
6M Performance:
+175.35%
1Y Performance:
+71.12%
1-Day Range:
$22.45
$24.60
1-Week Range:
$20.52
$24.60
52-Week Range:
$5.35
$24.60
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
23.46 | 1.24B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Jacobs Levy Equity Management Inc. Purchases New Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Siren L.L.C. Buys 247,347 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Sets New 52-Week HighWhat's Next? - MarketBeat
Invesco Ltd. Has $174,000 Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.4%Time to Sell? - MarketBeat
Granahan Investment Management LLC Buys 92,741 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug - Yahoo Finance
Checkpoint Capital L.P. Increases Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Trexquant Investment LP - MarketBeat
Russell Investments Group Ltd. Purchases New Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
What is Stoke Therapeutics Inc.’s valuation compared to sectorShare Buyback & Community Consensus Picks - Lancaster City Council
What’s the analyst consensus on Stoke Therapeutics Inc.New Guidance & Verified Stock Trade Ideas - beatles.ru
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 850 Shares of Stock - MarketBeat
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Placera.se
Stoke Therapeutics (NASDAQ:STOK) Reaches New 52-Week HighWhat's Next? - MarketBeat
Stoke Therapeutics stock reaches 52-week high at 20.5 USD By Investing.com - Investing.com Australia
108,087 Shares in Stoke Therapeutics, Inc. $STOK Bought by Nuveen LLC - MarketBeat
Will Stoke Therapeutics Inc. outperform its industry peersJuly 2025 Summary & Stepwise Trade Signal Guides - خودرو بانک
Stoke Therapeutics and the Potential of Zorevunersen in Redefining Dravet Syndrome Treatment - AInvest
Is Stoke Therapeutics Inc. part of any major indexQuarterly Market Review & Fast Moving Stock Trade Plans - خودرو بانک
Why is Stoke Therapeutics Inc. stock going upMarket Growth Review & Technical Entry and Exit Tips - خودرو بانک
Will breakout in Stoke Therapeutics Inc. lead to full recoveryJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Is Stoke Therapeutics Inc. still worth holding after the dipRisk Management & Technical Pattern Based Buy Signals - Newser
Volume spikes in Stoke Therapeutics Inc. stock – what they mean2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
Analyzing drawdowns of Stoke Therapeutics Inc. with statistical tools2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser
Published on: 2025-09-05 21:40:33 - خودرو بانک
Stoke Therapeutics stock reaches 52-week high at 20.5 USD - Investing.com
Price action breakdown for Stoke Therapeutics Inc.July 2025 Institutional & High Win Rate Trade Tips - Newser
Key metrics from Stoke Therapeutics Inc.’s quarterly data2025 Momentum Check & Expert Verified Movement Alerts - Newser
Applying Wyckoff theory to Stoke Therapeutics Inc. stock2025 Market Overview & Fast Moving Trade Plans - Newser
Relative strength of Stoke Therapeutics Inc. in sector analysisTrade Entry Summary & Entry Point Strategy Guides - Newser
Sector ETF performance correlation with Stoke Therapeutics Inc.Market Rally & Low Drawdown Investment Ideas - Newser
Charles Schwab Investment Management Inc. Sells 31,822 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Market reaction to Stoke Therapeutics Inc.’s recent newsWeekly Gains Report & Entry Point Strategy Guides - Newser
How to use Fibonacci retracement on Stoke Therapeutics Inc.Bull Run & Free Safe Entry Trade Signal Reports - Newser
A | Is Stoke Therapeutics, Inc. a turnaround storyQuarterly Growth Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can volume confirm reversal in Stoke Therapeutics Inc.Weekly Market Outlook & Precise Buy Zone Tips - Newser
What does recent volatility data suggest for Stoke Therapeutics Inc.Portfolio Update Report & Low Risk Investment Opportunities - Newser
Stoke Therapeutics Inc. recovery potential after sell off2025 Market Overview & Risk Managed Investment Entry Signals - Newser
Will Stoke Therapeutics Inc. bounce back from current supportQuarterly Profit Review & Short-Term High Return Ideas - Newser
Insider Sell: Kaye Edward M. MD Sells 61,885 Shares of Stoke The - GuruFocus
Will Stoke Therapeutics Inc. stock go up in YEARJuly 2025 Drop Watch & Consistent Profit Trading Strategies - خودرو بانک
DAFNA Capital Management LLC Buys 272,901 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Institutional scanner results for Stoke Therapeutics Inc.2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Bull Run & Technical Confirmation Trade Alerts - Newser
Stoke Therapeutics' Insider Sales: A Cautionary Tale or a Sign of Strength? - AInvest
Assessing Insider Selling Trends at Stoke Therapeutics (STOK): Liquidity Moves or Loss of Confidence? - AInvest
Stoke Therapeutics Executives Buy and Sell Shares in August and September 2025. - AInvest
Will Stoke Therapeutics Inc. benefit from rate cutsQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - خودرو بانک
What analysts say about Stoke Therapeutics Inc. stockJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - خودرو بانک
Stoke Therapeutics shares fall 2.40% premarket after presenting data from Phase 1/2a and open-label extension studies of zorevunersen. - AInvest
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):